MBX (STOCKS)
MBX Biosciences, Inc. Common Stock
$38.000000
+3.000000 (+8.57%)
Prev close: $35.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Peter Kent Hawryluk
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,705.84M
- Employees
- 43
- P/E (TTM)
- -15.88
- P/B (TTM)
- 4.38
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.63 | $-0.70 | +0.0707 | +10.09% |
|
Jun 2025 (Q2)
|
$-0.58 | $-0.77 | +0.1874 | +24.42% |
|
Mar 2025 (Q1)
|
$-0.71 | $-0.78 | +0.0677 | +8.71% |
|
Dec 2024 (Q4)
|
$-0.47 | $-0.58 | +0.1091 | +18.84% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $90.87M |
| Research and Development | $74.62M |
| Other Operating Expenses | $16.25M |
| Operating Income/Loss | -$90.87M |
| Income/Loss From Continuing Operations After Tax | -$80.47M |
| Income/Loss From Continuing Operations Before Tax | -$80.47M |
| Net Income/Loss | -$80.50M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$80.47M |
| Net Income/Loss Available To Common Stockholders, Basic | -$80.50M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $7.68 |
| Diluted Earnings Per Share | $7.68 |
| Basic Average Shares | 108,695,940 |
| Diluted Average Shares | 108,695,940 |
| Assets | $400.08M |
| Current Assets | $397.50M |
| Cash | $391.70M |
| Other Current Assets | $5.80M |
| Noncurrent Assets | $2.57M |
| Fixed Assets | $2.00M |
| Other Non-current Assets | $570.00K |
| Liabilities | $12.54M |
| Current Liabilities | $12.06M |
| Accounts Payable | $3.77M |
| Other Current Liabilities | $8.29M |
| Noncurrent Liabilities | $476.00K |
| Equity | $387.54M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $387.54M |
| Liabilities And Equity | $400.08M |
| Net Cash Flow From Operating Activities | -$77.69M |
| Net Cash Flow From Operating Activities, Continuing | -$77.69M |
| Net Cash Flow From Investing Activities | -$21.08M |
| Net Cash Flow From Investing Activities, Continuing | -$21.08M |
| Net Cash Flow From Financing Activities | $189.02M |
| Net Cash Flow From Financing Activities, Continuing | $189.02M |
| Net Cash Flow | $90.26M |
| Net Cash Flow, Continuing | $90.26M |
| Comprehensive Income/Loss | -$80.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$80.45M |
| Other Comprehensive Income/Loss | $53.00K |
| Other Comprehensive Income/Loss Attributable To Parent | $48.00K |